BofA Downgrades Sarepta, But Hikes Price Target

By: via Benzinga
In a report published Thursday, BofA Merrill Lynch analysts downgraded the rating on Sarepta Therapeutics Inc (NASDAQ: SRPT) to Neutral, ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.